Neumora Q2 net loss $58.7M; Phase 3 MDD data on track for Q4 2024

Neumora Therapeutics, Inc.

2024-Q2 EPS reported -$0.71

Cash $371.6M as of June 30, 2024, expected to fund operations into 2026.
R&D expense $48.6M (up from $32.8M); G&A $15.2M (up from $9.3M).
Topline data from KOASTAL-1 Phase 3 study of navacaprant in MDD expected Q4 2024.
Phase 2 trial for navacaprant in bipolar depression initiated; Phase 1b of NMRA-511 in Alzheimer's agitation started.
NMRA-266 study on clinical hold; additional M4 PAM IND submission expected first half 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.